TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas

Modern Pathology

Volumn 27, Issue 4, 2014, Pages 502-508

  Griewank, Klaus G ^a   Schilling, Bastian ^a   Murali, Rajmohan ^b   Bielefeld, Nicola ^a   Schwamborn, Marion ^a   Sucker, Antje ^a   Zimmer, Lisa ^a   Hillen, Uwe ^a   Schaller, Jörg ^c   Brenn, Thomas ^d   Schadendorf, Dirk ^a   Mentzel, Thomas ^e  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Dermatopathology Duisburg   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e Dermatopathologische Gemeinschaftspraxis   (Germany)

Author keywords

atypical fibroxanthoma; cancer genetics; dermatology; pleomorphic dermal sarcoma; telomerase; TERT; undifferentiated pleomorphic sarcoma

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; FIBROXANTHOMA; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PLEOMORPHIC DERMAL SARCOMA; PRIORITY JOURNAL; PROMOTER REGION; SKIN TUMOR; TERT GENE; ULTRAVIOLET RADIATION; VERY ELDERLY; ENZYMOLOGY; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SARCOMA; XANTHOMATOSIS;

TELOMERASE; TERT PROTEIN, HUMAN;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; SARCOMA; SKIN NEOPLASMS; TELOMERASE; XANTHOMATOSIS;

EID: 84897535970     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.168     Document Type: Article

References (29)

1. Iorizzo LJ III, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg 2011;37: 146-57.
2. Gru AA, Santa Cruz DJ. Atypical fibroxanthoma: a selective review. Semin Diagn Pathol 2013;30:4-12.
3. McCalmont TH. AFX: what we now know. J Cutan Pathol 2011;38:853-6.
4. McCoppin HH, Christiansen D, Stasko T, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Dermatol Surg 2012;38:230-9.
5. McCalmont TH. Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol 2012;39:8.
6. Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 2012;36:1317-26.
7. Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 1963;16:331-44.
8. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006;48:3-12.
9. Henderson MT, Hollmig ST. Malignant fibrous histiocytoma: changing perceptions and management challenges. J Am Acad Dermatol 2012;67:1335-41.
10. Hartel PH, Jackson J, Ducatman BS, Zhang P. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker. J Cutan Pathol 2006;33(Suppl 2):24-8.
11. Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer 1997;79: 2115-24.
12. Dei Tos AP, Maestro R, Doglioni C, et al. Ultravioletinduced p53 mutations in atypical fibroxanthoma. Am J Pathol 1994;145:11-7.
13. Sakamoto A, Oda Y, Itakura E, et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol 2001;14: 581-8.
14. Sakamoto A, Oda Y, Itakura E, et al. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum Pathol 2001;32: 1225-31.
15. Mihic-Probst D, Zhao J, Saremaslani P, et al. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res 2004;24: 19-26.
16. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-9.
17. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61.
18. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191-6.
19. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of selfrenewal. Proc Natl Acad Sci USA 2013;110:6021-6.
20. Ito A, Yamada N, Yoshida Y, Morino S, Yamamoto O. Myofibroblastic differentiation in atypical fibroxanthomas occurring on sun-exposed skin and in a burn scar: an ultrastructural and immunohistochemical study. J Cutan Pathol 2011;38:670-6.
21. Beer TW, Drury P, Heenan PJ. Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. Am J Dermatopathol 2010;32:533-40.
22. Weedon D, Kerr JF. Atypical fibroxanthoma of skin: an electron microscope study. Pathology 1975;7:173-7.
23. Starink TH, Hausman R, Van Delden L, Neering H. Atypical fibroxanthoma of the skin. Presentation of 5 cases and a review of the literature. Br J Dermatol 1977;97:167-77.
24. de Feraudy S, Mar N, McCalmont TH. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol 2008; 32:1111-22.
25. Jensen K, Wilkinson B, Wines N, Kossard S. Procollagen 1 expression in atypical fibroxanthoma and other tumors. J Cutan Pathol 2004;31:57-61.
26. Alguacil-Garcia A, Unni KK, Goellner JR, Winkelmann RK. Atypical fibroxanthoma of the skin: an ultrastructural study of two cases. Cancer 1977;40:1471-80.
27. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8.
28. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005;579:859-62.
29. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell 2013;152:390-3.